These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 12127430)
41. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin]. Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759 [TBL] [Abstract][Full Text] [Related]
42. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Dalgard O; Bjøro K; Hellum KB; Myrvang B; Ritland S; Skaug K; Raknerud N; Bell H Hepatology; 2004 Dec; 40(6):1260-5. PubMed ID: 15558712 [TBL] [Abstract][Full Text] [Related]
43. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832 [TBL] [Abstract][Full Text] [Related]
44. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. Bruno S; Cammà C; Di Marco V; Rumi M; Vinci M; Camozzi M; Rebucci C; Di Bona D; Colombo M; Craxì A; Mondelli MU; Pinzello G J Hepatol; 2004 Sep; 41(3):474-81. PubMed ID: 15336451 [TBL] [Abstract][Full Text] [Related]
45. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group. Bell H; Hellum K; Harthug S; Myrvang B; Ritland S; Maeland A; von der Lippe B; Bjøro K; Skaug K; Gutigard BG; Raknerud N; Simmonds P Scand J Gastroenterol; 1999 Feb; 34(2):194-8. PubMed ID: 10192200 [TBL] [Abstract][Full Text] [Related]
46. High-dose interferon-alpha2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-alpha monotherapy. Hass HG; Kreysel C; Fischinger J; Menzel J; Kaiser S World J Gastroenterol; 2005 Sep; 11(34):5342-6. PubMed ID: 16149143 [TBL] [Abstract][Full Text] [Related]
47. Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection. Lin TY; Yeh ML; Huang CI; Chen YL; Dai CY; Huang JF; Lin ZY; Chen SC; Huang CF; Yu ML; Chuang WL Kaohsiung J Med Sci; 2017 Jun; 33(6):284-289. PubMed ID: 28601232 [TBL] [Abstract][Full Text] [Related]
48. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Shiffman ML; Di Bisceglie AM; Lindsay KL; Morishima C; Wright EC; Everson GT; Lok AS; Morgan TR; Bonkovsky HL; Lee WM; Dienstag JL; Ghany MG; Goodman ZD; Everhart JE; Gastroenterology; 2004 Apr; 126(4):1015-23; discussion 947. PubMed ID: 15057741 [TBL] [Abstract][Full Text] [Related]
49. Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus. Tamai H; Shingaki N; Mori Y; Moribata K; Kawashima A; Maeda Y; Niwa T; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Ichinose M Gut Liver; 2016 Jul; 10(4):617-23. PubMed ID: 26601828 [TBL] [Abstract][Full Text] [Related]
50. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin. Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916 [TBL] [Abstract][Full Text] [Related]
51. Interleukin-2 plus ribavirin versus interferon-alpha-2b plus ribavirin in patients with chronic hepatitis C who did not respond to previous interferon-alpha-2b treatment. Malaguarnera M; Pistone G; Neri S; Romano M; Brogna A; Musumeci S BioDrugs; 2004; 18(6):407-13. PubMed ID: 15571424 [TBL] [Abstract][Full Text] [Related]
52. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. McHutchison JG; Manns M; Patel K; Poynard T; Lindsay KL; Trepo C; Dienstag J; Lee WM; Mak C; Garaud JJ; Albrecht JK; Gastroenterology; 2002 Oct; 123(4):1061-9. PubMed ID: 12360468 [TBL] [Abstract][Full Text] [Related]
53. Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. Berenguer M; Prieto M; Palau A; Carrasco D; Rayón JM; Calvo F; Berenguer J Eur J Gastroenterol Hepatol; 2004 Nov; 16(11):1207-12. PubMed ID: 15489583 [TBL] [Abstract][Full Text] [Related]
54. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Rossignol JF; Elfert A; El-Gohary Y; Keeffe EB Gastroenterology; 2009 Mar; 136(3):856-62. PubMed ID: 19135998 [TBL] [Abstract][Full Text] [Related]
55. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin. Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079 [TBL] [Abstract][Full Text] [Related]
56. Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. Schmitz V; Kiessling A; Bahra M; Puhl G; Kahl A; Berg T; Neuhaus R; Neuhaus P; Neumann U Ann Transplant; 2007; 12(3):22-7. PubMed ID: 18290566 [TBL] [Abstract][Full Text] [Related]
57. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load. Toyoda H; Kumada T; Tada T; Arakawa T; Hayashi K; Honda T; Katano Y; Goto H J Gastroenterol Hepatol; 2010 Jun; 25(6):1072-8. PubMed ID: 20594221 [TBL] [Abstract][Full Text] [Related]
58. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. Wirth S; Ribes-Koninckx C; Calzado MA; Bortolotti F; Zancan L; Jara P; Shelton M; Kerkar N; Galoppo M; Pedreira A; Rodriguez-Baez N; Ciocca M; Lachaux A; Lacaille F; Lang T; Kullmer U; Huber WD; Gonzalez T; Pollack H; Alonso E; Broue P; Ramakrishna J; Neigut D; Valle-Segarra AD; Hunter B; Goodman Z; Xu CR; Zheng H; Noviello S; Sniukiene V; Brass C; Albrecht JK J Hepatol; 2010 Apr; 52(4):501-7. PubMed ID: 20189674 [TBL] [Abstract][Full Text] [Related]
59. Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months. Di Marco V; Almasio P; Vaccaro A; Ferraro D; Parisi P; Cataldo MG; Di Stefano R; Craxì A J Hepatol; 2000 Sep; 33(3):456-62. PubMed ID: 11020002 [TBL] [Abstract][Full Text] [Related]
60. Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT. Jacobson IM; Ahmed F; Russo MW; Lebovics E; Dieterich DT; Esposito SP; Bach N; Klion F; Tobias H; Antignano L; Brown RS; Gabbaizadeh D; Geders J; Levendoglu H Am J Gastroenterol; 2004 Sep; 99(9):1700-5. PubMed ID: 15330905 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]